Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency
November 16, 2020 08:00 ET
|
Receptor Holding
SEATTLE, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). ...
Receptor Life Sciences Names Gregory Mayes to Board of Directors
November 11, 2020 08:00 ET
|
Receptor Holding
SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences (Receptor) today announced the appointment of Gregory T. Mayes, J.D. to its Board of Directors. Mr. Mayes is an expert in...
New Clinical Pharmacokinetic Study Demonstrates Proof-of-Concept for Receptor Life Science’s Investigational Cannabinoid-based Product Candidates
September 14, 2020 08:00 ET
|
Receptor Holding
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Data from an initial proof-of-concept clinical pharmacokinetic study demonstrate that Receptor Life Sciences' research team has found a way to address...
Receptor Life Sciences Secures U.S. Patent for its Oral Absorption Enhancing Excipients with Cannabinoids
March 19, 2020 12:40 ET
|
Receptor Holding
SEATTLE, March 19, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences (“RLS”), a leading biopharmaceutical company developing FDA regulated oral and inhaled cannabinoid medicines, today announced that...
Receptor Holdings Expands Board of Directors with Pharmaceutical Industry Business Development Leader James Weissman
October 07, 2019 08:00 ET
|
Receptor Holding
SEATTLE, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Receptor Holdings (RHI) and its subsidiary, Receptor Life Sciences, Inc. (RLS), a leading biopharmaceutical company developing FDA-regulated oral and...
Nationally Recognized Medical Experts Join Receptor Life Science’s Scientific Advisory Board to Guide the Development of New Cannabinoid Therapies
June 24, 2019 08:00 ET
|
Receptor Holding
SEATTLE, June 24, 2019 (GLOBE NEWSWIRE) -- Receptor Life Sciences (RLS), a leader in FDA-regulated cannabinoid medicine drug development using proprietary delivery technologies, today announced the...
Receptor Holdings Adds Alex Casdin to Board of Directors
April 08, 2019 08:50 ET
|
Receptor Holding
SEATTLE, April 08, 2019 (GLOBE NEWSWIRE) -- Alexander W. Casdin, Founder, CEO, and Portfolio Manager of Reneo Capital Management LP, has been named to the Board of Directors of Receptor Holdings...